Cesar Rodriguez

2.0k total citations
22 papers, 334 citations indexed

About

Cesar Rodriguez is a scholar working on Hematology, Oncology and Radiology, Nuclear Medicine and Imaging. According to data from OpenAlex, Cesar Rodriguez has authored 22 papers receiving a total of 334 indexed citations (citations by other indexed papers that have themselves been cited), including 17 papers in Hematology, 11 papers in Oncology and 7 papers in Radiology, Nuclear Medicine and Imaging. Recurrent topics in Cesar Rodriguez's work include Multiple Myeloma Research and Treatments (17 papers), Monoclonal and Polyclonal Antibodies Research (7 papers) and CAR-T cell therapy research (5 papers). Cesar Rodriguez is often cited by papers focused on Multiple Myeloma Research and Treatments (17 papers), Monoclonal and Polyclonal Antibodies Research (7 papers) and CAR-T cell therapy research (5 papers). Cesar Rodriguez collaborates with scholars based in United States, Germany and Belgium. Cesar Rodriguez's co-authors include Peter M. Voorhees, Anita D’Souza, Ben Buelow, Ravi Vij, Nina Shah, Shaji Kumar, Orlando F. Bueno, Akshanth R. Polepally, Kevin J. Freise and Barry Paul and has published in prestigious journals such as Journal of Clinical Oncology, Blood and Drugs.

In The Last Decade

Cesar Rodriguez

21 papers receiving 324 citations

Peers

Cesar Rodriguez
Keqin Qi United States
Martine Poelman Belgium
Federica Cocito Italy
Tiffany Lin United States
Syed Osman Ahmed Saudi Arabia
Frank G. Basile United States
Zitong Chen China
Adir Shaulov Israel
Anna Pieczonka Poland
Keqin Qi United States
Cesar Rodriguez
Citations per year, relative to Cesar Rodriguez Cesar Rodriguez (= 1×) peers Keqin Qi

Countries citing papers authored by Cesar Rodriguez

Since Specialization
Citations

This map shows the geographic impact of Cesar Rodriguez's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Cesar Rodriguez with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Cesar Rodriguez more than expected).

Fields of papers citing papers by Cesar Rodriguez

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Cesar Rodriguez. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Cesar Rodriguez. The network helps show where Cesar Rodriguez may publish in the future.

Co-authorship network of co-authors of Cesar Rodriguez

This figure shows the co-authorship network connecting the top 25 collaborators of Cesar Rodriguez. A scholar is included among the top collaborators of Cesar Rodriguez based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Cesar Rodriguez. Cesar Rodriguez is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Schinke, Carolina, Binod Dhakal, Tiffany Richards, et al.. (2024). Real-world experience with clinical management of talquetamab in relapsed/refractory multiple myeloma: a qualitative study of US healthcare providers. Current Medical Research and Opinion. 40(10). 1705–1711. 7 indexed citations
2.
Weisel, Katja, Anita D’Souza, David D. Hurd, et al.. (2023). P862: A PHASE 1 FIRST-IN-HUMAN MONOTHERAPY STUDY OF ABBV-383, A BCMA × CD3 BISPECIFIC T-CELL–REDIRECTING ANTIBODY, IN RELAPSED/REFRACTORY MULTIPLE MYELOMA. HemaSphere. 7(S3). e0036307–e0036307. 1 indexed citations
3.
D’Souza, Anita, Nina Shah, Cesar Rodriguez, et al.. (2022). A Phase I First-in-Human Study of ABBV-383, a B-Cell Maturation Antigen × CD3 Bispecific T-Cell Redirecting Antibody, in Patients With Relapsed/Refractory Multiple Myeloma. Journal of Clinical Oncology. 40(31). 3576–3586. 84 indexed citations
4.
Paul, Barry, Cesar Rodriguez, & Saad Z. Usmani. (2022). BCMA-Targeted Biologic Therapies: The Next Standard of Care in Multiple Myeloma Therapy. Drugs. 82(6). 613–631. 20 indexed citations
5.
Rodriguez, Cesar, Katja Weisel, Rachid Baz, et al.. (2022). Dose Escalation and Expansion of Abbv-383 in Combination with Anti-Cancer Regimens in Relapsed or Refractory Multiple Myeloma. Blood. 140(Supplement 1). 7326–7327. 2 indexed citations
6.
Rodriguez, Cesar, Jonathan L. Kaufman, Jacob P. Laubach, et al.. (2022). Daratumumab (DARA) + lenalidomide, bortezomib, and dexamethasone (RVd) in transplant-eligible newly diagnosed multiple myeloma (NDMM): A post hoc analysis of sustained minimal residual disease (MRD) negativity from GRIFFIN.. Journal of Clinical Oncology. 40(16_suppl). 8011–8011. 4 indexed citations
7.
Kumar, Shaji, Anita D’Souza, Nina Shah, et al.. (2021). A Phase 1 First-in-Human Study of Tnb-383B, a BCMA x CD3 Bispecific T-Cell Redirecting Antibody, in Patients with Relapsed/Refractory Multiple Myeloma. Blood. 138(Supplement 1). 900–900. 36 indexed citations
8.
Rodriguez, Cesar. (2021). An Overview of Organoid and 3-Dimensional Models in Multiple Myeloma. The Cancer Journal. 27(3). 239–246. 3 indexed citations
9.
Voorhees, Peter M., Cesar Rodriguez, Brandi Reeves, et al.. (2021). Daratumumab plus RVd for newly diagnosed multiple myeloma: final analysis of the safety run-in cohort of GRIFFIN. Blood Advances. 5(4). 1092–1096. 18 indexed citations
10.
11.
Bar, Merav, Susan M. Ott, E. Michael Lewiecki, et al.. (2020). Bone Health Management After Hematopoietic Cell Transplantation: An Expert Panel Opinion from the American Society for Transplantation and Cellular Therapy. Biology of Blood and Marrow Transplantation. 26(10). 1784–1802. 10 indexed citations
12.
Nooka, Ajay K., Jonathan L. Kaufman, Cesar Rodriguez, et al.. (2020). MM-350: Daratumumab (DARA) + Lenalidomide/Bortezomib/Dexamethasone (RVd) in African American/Black Patients (Pts) with Transplant-Eligible Newly Diagnosed Multiple Myeloma (NDMM): Subgroup Analysis of GRIFFIN. Clinical Lymphoma Myeloma & Leukemia. 20. S308–S309. 1 indexed citations
13.
Rodriguez, Cesar, Anita D’Souza, Nina Shah, et al.. (2020). Initial Results of a Phase I Study of TNB-383B, a BCMA x CD3 Bispecific T-Cell Redirecting Antibody, in Relapsed/Refractory Multiple Myeloma. Blood. 136(Supplement 1). 43–44. 45 indexed citations
14.
15.
Tooze, Janet A., et al.. (2018). Tacrolimus Levels and Correlation to Age and Weight Calculation. Biology of Blood and Marrow Transplantation. 24(3). S337–S337. 1 indexed citations
16.
Rodriguez, Cesar, Roy E. Strowd, & David D. Grier. (2017). Anaplastic Myeloma Arising from Myeloma: Successful Management of Two Diseases in an Individual. Blood. 130. 5410–5410. 2 indexed citations
17.
18.
19.
Johnston, Bridget, et al.. (2015). Living well with dementia: enhancing dignity and quality of life, using a novel intervention, Dignity Therapy. International Journal of Older People Nursing. 11(2). 107–120. 44 indexed citations
20.
Rodriguez, Cesar, et al.. (2014). A phase II trial of extended interval port-a-cath (PAC) flushes.. Journal of Clinical Oncology. 32(15_suppl). e17606–e17606. 1 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Keqin Qi Breakdown of academic impact, for papers by Martine Poelman Breakdown of academic impact, for papers by Federica Cocito Breakdown of academic impact, for papers by Tiffany Lin Breakdown of academic impact, for papers by Syed Osman Ahmed Breakdown of academic impact, for papers by Frank G. Basile Breakdown of academic impact, for papers by Zitong Chen Breakdown of academic impact, for papers by Adir Shaulov Breakdown of academic impact, for papers by Anna Pieczonka
Rankless by CCL
2026